Global Healthcare Opportunities, the UK specialist investor in global healthcare, today announces the final close of its fourth fund, GHO Capital IV LP, raising over €2.5 billion of capital available to invest.
Fund IV further diversifies GHO’s investor base, with strong support from both existing investors as well as a significant amount of capital from over 30 new institutional investors across Europe, North America, Asia Pacific and the Middle East.
Mike Mortimer, Alan Mackay and Andrea Ponti, the Managing Partners at GHO Capital commented: “We are witnessing a golden era of healthcare innovation, driven by the convergence of advanced science, digital technologies, and data. GHO Capital is at the forefront, delivering strong returns while enabling better, faster and more accessible healthcare.
“Fund IV’s success against the backdrop of a challenging fundraising environment reflects confidence in our strategy, transatlantic reach and consistent track record of outperformance across the healthcare ecosystem.”
In 2025, the European healthcare and HealthTech ecosystem has remained active across both early- and growth-stage segments.
Notable startup fundraises covered by EU-Startups include ViCentra (Netherlands, €72.4 million) to expand its insulin-delivery platform, Teton.ai (Denmark, €17 million) to scale its AI-driven patient-monitoring technology, and RDS (France, €14 million) to industrialise connected-patch production for remote care.
Digital-health ventures are also attracting significant backing, such as SheMed (UK, €43 million) in personalised women’s healthcare and Juisci (France, €5.5 million) with its AI-powered scientific-knowledge platform for clinicians.
Against this backdrop, GHO Capital’s final close for Fund IV represents a substantial institutional-scale commitment to European and transatlantic healthcare opportunities. While startups are drawing tens of millions in venture rounds, GHO’s vehicle positions it to support mid-market expansion and consolidation across BioPharma, MedTech, Life-Science Tools, and HealthTech.
“We are grateful for the trust from both existing and new investors as we partner with world-class management teams to build the next generation of healthcare leaders,” added the Managing Partners.
Founded in 2014, Global Healthcare Opportunities, including investment manager GHO Capital Management Limited and investment advisor GHO Capital Partners Advisory Ltd., is a specialist healthcare investment firm.
As GHO’s largest fund to date, 25% larger than its predecessor, Fund IV brings total AUM to c.€9 billion, making GHO the largest healthcare specialist private equity firm headquartered in Europe.
GHO remains well-positioned to capitalise on mid-market opportunities in the rapidly growing technical healthcare sector across BioPharma, MedTech, Advisory & Data, Life Science Tools & Diagnostics and HealthTech.
Beyond fundraising, GHO has made strong progress in 2025, signing three new platform investments and several add-on acquisitions. New investments include:
- Avid Bioservices, a CDMO focused on development and CGMP manufacturing of biologics,
- Scientist.com, an AI-powered R&D orchestration platform serving pharmaceutical and biotech companies
- FotoFinder Systems, a manufacturer of cutting-edge skin diagnostics and imaging solutions.
Since closing GHO Capital III in 2021, GHO has expanded its transatlantic footprint with 19 new hires, taking the team to over 75 professionals who provide on the ground support for its portfolio across Europe and the US.
The firm has also strengthened its senior leadership with the appointment of a new Partner in 2024 alongside five new integrated Operating Partners and Senior Advisors, who bring deep industry insights to support GHO’s thematic investment and value creation approach.
Read the orginal article: https://www.eu-startups.com/2025/10/london-based-gho-capital-boosts-healthcare-fund-size-by-25-to-e2-5-billion/
